Latest action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Speeds up the approval process for biosimilar medications in the United States.
The problem
Current biosimilar review processes may be slow and complicated, potentially delaying patient access to more affordable biologic drug alternatives.
The proposal
Streamlines and simplifies the regulatory review procedures that biosimilar products must go through before receiving approval from health authorities.
The impact
Patients could gain faster access to cheaper biologic medicines. Drug makers would have clearer approval paths. Healthcare systems could reduce medication costs.
Streamlined review means biosimilar medications reach patients more quickly. This allows people to access cheaper versions of expensive biologic drugs sooner. Faster availability reduces treatment delays for patients.
Biosimilars are cheaper copies of expensive biologic drugs. Faster approval means more affordable options enter the market sooner. This can reduce medication costs for patients and healthcare systems.
Streamlined processes give companies a clearer path to approval. This reduces confusion and paperwork for manufacturers. Clearer rules may encourage more companies to develop biosimilar products.
Easier approval processes attract more competitors to the biosimilar market. More competitors drive prices down through competition. This benefits patients and healthcare systems through lower costs.
Streamlining review processes might reduce the time spent checking safety and quality. Faster approval could mean less thorough testing of biosimilar products. Patient safety could be at risk if reviews become too quick.
Simplified procedures may result in less regulatory oversight of manufacturers. With fewer checks, some quality problems might be missed. This could harm patients if defective products reach the market.
Faster biosimilar approval threatens profits for companies making original biologic drugs. These companies may reduce research into new treatments if profits fall. Innovation in new drug development could slow down.
Changing approval processes requires training and resources for regulatory agencies. The transition period could create confusion about which rules apply. Agencies may struggle to implement new procedures effectively.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.